SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that the Company will present data from two ongoing Phase 2 clinical trials of picoplatin at two upcoming American Society of Clinical Oncology (ASCO) Symposia.
In January, the Company will present updated data from its Phase 2 trial of picoplatin in patients with metastatic colorectal cancer at ASCO's 2009 Gastrointestinal (GI) Cancers Symposium in San Francisco. In February, updated data from the ongoing Phase 2 trial of picoplatin in patients with metastatic hormone refractory (or castration resistant) prostate cancer will be presented at ASCO's Genitourinary (GU) Cancers Symposium in Orlando, Fla.
Presentation details are as follows: -- The ASCO 2009 GI Cancers Symposium, San Francisco -- Randomized Phase 2 study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to mFOLFOX-6 as first-line therapy for colorectal cancer (CRC) -- R. H. Earhart, S. V. Cheporov, O. A. Gladkov, M. Y. Biakhov, G. S. Baker, H. B. Breitz -- Saturday, January 17, 12:30-1:30 -- The ASCO 2009 GU Cancers Symposium, Orlando, Fla. -- Results of a Phase 2 study of picoplatin with docetaxel and prednisone in first-line treatment of metastatic hormone refractory prostate cancer (HRPC) -- R. Earhart, L. Roman, N. Lopatkin, P. Karlov, H. Breitz, David Karlin, R. De Jager -- Friday, February 27, 11:45-1:15
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
|SOURCE Poniard Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved